Along these lines, liraglutide (a glucagon-like peptide-1 receptor agonist) was shown to increase peripheral insulin sensitivity, attenuate memory impairment, and reduce amyloid plaque deposition in aged transgenic APP/presenilin-1 (PS1) mice, a widely used animal model of AD (Mcclean and Hölscher, 2014). Here, APP is linked to amyloidosis.